

NEW J-CODE (J0791)¹

For ADAKVEO® (crizanlizumab-tmca)
1 unit = 5 mg
Effective July 1, 2020



Miscellaneous coding and billing reference sheet: Hospital outpatient setting

Sample UB-04 CMS-1450 claim form² for ADAKVEO® (crizanlizumab-tmca) for IV infusion

◆ Hospital outpatient administration

Although this sheet provides information that should facilitate the claims process, all coding information is for reference purposes only. Novartis does not guarantee payment.

The health care billing environment is constantly evolving to keep pace with scientific advances and financial constraints. Information specific to billing and coding is subject to change and should be verified for each patient prior to treatment. A provider should contact patients' payers directly for any revised or additional requirements, information, or guidance.

This sample claim form assumes a 60-kg patient who received a dose of 5 mg/kg or 300 mg via a 30-minute infusion on July 1, 2020.

Box 42: Enter the appropriate revenue code corresponding with the HCPCS code in box 44, and 0510 for clinic services (eg, 0636 revenue code for pharmacy drugs that require detailed coding).

Box 43: Enter a detailed drug description for the payer. The N4 indicator is listed first, the 11-digit National Drug Code number is listed second, a code describing the unit of measurement qualifier is listed third (eg, ML for milliliters), and the unit quantity is listed at the end. Example: N400078088361ML30

Box 44: Enter the appropriate HCPCS code for ADAKVEO: J0791, Injection, crizanlizumab-tmca, 5 mg.¹ The JW modifier must be used to report the amount of drug in single-dose or single-use packaging that is discarded and eligible for payment.³ To report the administration procedure, enter an appropriate CPT code (eg, 96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis [specify substance or drug]; initial, up to 1 hour).⁴

Box 46: Enter the total number of units of service. Confirm units with payer.

Box 47: Enter the total amount the facility actually charged for the product.

Box 67A-67C: Enter the appropriate ICD-10-CM diagnosis code (eg, D57.1 for Sick cell disease without crisis).⁵ Code to the highest level of specificity.

The form is a UB-04 CMS-1450 claim form. Key sections and annotations include:

- Box 42:** Revenue code 0636 and 0510.
- Box 43:** Drug description: N400078088361ML30.
- Box 44:** HCPCS codes: J0791 and 96365.
- Box 46:** Units of service: 60.
- Box 47:** Total charges: \$\$. Total amount due: \$\$. Non-covered charges: \$.
- Box 67A-67C:** ICD-10-CM diagnosis code: D57.1.
- Remarks:** Injection, crizanlizumab-tmca, 300mg.

IMPORTANT INFORMATION: The coding, coverage, and payment information contained herein is gathered from various resources, general in nature, and subject to change without notice. Third-party payment for medical products and services is affected by numerous factors. It is always the provider's responsibility to determine the appropriate health care setting, and to submit true and correct claims for those products and services rendered. Providers should contact third-party payers for specific information on their coding, coverage, and payment policies. Information and materials are provided to assist health care providers, but the responsibility to determine coverage, reimbursement, and appropriate coding for a particular patient and/or procedure remains at all times with the provider.

ADAKVEO Support at PANO | Phone: 1-800-282-7630 Monday-Friday, 9 AM to 8 PM ET | hcp.novartis.com/access/

Please see [page 2](#) for Indication and Important Safety Information. Please [click here](#) for full Prescribing Information.

INDICATION

ADAKVEO® (crizanlizumab-tmca) is indicated to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients, aged 16 years and older, with sickle cell disease.

IMPORTANT SAFETY INFORMATION

Infusion-Related Reactions

In the SUSTAIN clinical trial, infusion-related reactions (defined as occurring within 24 hours of infusion) were observed in 2 (3%) patients treated with ADAKVEO 5 mg/kg. Monitor patients for signs and symptoms of infusion-related reactions, which may include fever, chills, nausea, vomiting, fatigue, dizziness, pruritus, urticaria, sweating, or shortness of breath or wheezing. Discontinue ADAKVEO infusion for severe reactions and institute appropriate medical care.

Laboratory Test Interference: Platelet Counts

Interference with automated platelet counts (platelet clumping) has been observed following administration of ADAKVEO, in particular, when blood samples were collected in tubes containing EDTA.

Run blood samples within 4 hours of blood collection or collect blood samples in tubes containing citrate. When needed, estimate platelet count via peripheral blood smear.

Pregnancy

Based on animal data ADAKVEO has the potential to cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. ADAKVEO should only be used during pregnancy if the expected benefit to the patient justifies the potential risk to the fetus.

Most Common Adverse Reactions

The most frequently reported adverse reactions ($\geq 10\%$) in patients treated with ADAKVEO were nausea (18%), arthralgia (18%), back pain (15%), and pyrexia (11%).

Other Clinically Important Adverse Reactions

Clinically relevant adverse reactions (all grades) that were reported in $< 10\%$ of patients treated with ADAKVEO included: oropharyngeal pain, abdominal pain (abdominal pain, upper abdominal pain, lower abdominal pain, abdominal discomfort, and abdominal tenderness), diarrhea, vomiting, pruritus (pruritus and vulvovaginal pruritus), musculoskeletal chest pain, myalgia, infusion-site reaction (infusion-site extravasation, infusion-site pain, and infusion-site swelling), and infusion-related reaction.

Please see full Prescribing Information [here](#).

References: **1.** Centers for Medicare & Medicaid Services. Healthcare Common Procedure Coding System (HCPCS) Application Summaries and Coding Decisions. <https://www.cms.gov/files/document/2020-hcpcs-application-summary-quarter-1-2020-drugs-and-biologicals-updated-04142020.pdf>. Accessed April 21, 2020. **2.** Centers for Medicare & Medicaid Services. CMS Manual System. Details for title: CMS 1450 (UB-04). <https://www.cms.gov/Regulations-and-Guidance/Legislation/PaperworkReductionActof1995/PRA-Listing-Items/CMS-1450>. Accessed May 28, 2020. **3.** Centers for Medicare & Medicaid Services. Medicare Program JW Modifier: Drug/Biological Amount Discarded/Not Administered to Any Patient Frequently Asked Questions. <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Downloads/JW-Modifier-FAQs.pdf>. Accessed May 13, 2020. **4.** Find-A-Code. 96365 - CPT® Code in category: Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug). InnoviHealth Systems, Inc. www.findacode.com/code.php?set=CPT&c=96365. Accessed May 26, 2020. **5.** Centers for Medicare and Medicaid Services. 2020 ICD-10-CM. <https://www.cms.gov/Medicare/Coding/ICD10/2020-ICD-10-CM>. Accessed May 28, 2020.



Novartis Pharmaceuticals Corporation
One Health Plaza
East Hanover, New Jersey 07936-1080

© 2020 Novartis

6/20



CZB-1231213